- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Prenetics Global Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 24.11. | Prenetics executives purchase $1.4 million in company stock | 1 | Investing.com | ||
| 24.11. | Prenetics executives buy $1.45M in company stock | 2 | Seeking Alpha | ||
| 24.11. | Prenetics-Management investiert 1,45 Millionen US-Dollar in eigene Aktien | 1 | Investing.com Deutsch | ||
| PRENETICS GLOBAL Aktie jetzt für 0€ handeln | |||||
| 24.11. | Prenetics Global Limited: Prenetics Executives Announce Open Market Share Purchases Totaling Approx. $1.45 Million | 2 | GlobeNewswire (USA) | ||
| 17.11. | Prenetics Global Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 14.11. | Prenetics Global Limited: Cantor Fitzgerald Reiterates Overweight Rating on Prenetics with Price Target of $31 Following Strong IM8 Growth | 328 | GlobeNewswire (Europe) | IM8's Strong Unit Economics-60% Margins and 3.9-Month Payback-Central to Cantor's Bullish Outlook Cantor Notes PRE's ~$120M Liquidity and 387 BTC Treasury as Strengthening the Company's Financial... ► Artikel lesen | |
| 12.11. | Cantor Fitzgerald lowers Prenetics stock price target to $31 on Q3 results | 2 | Investing.com | ||
| 10.11. | Prenetics Global GAAP EPS of -$0.53, revenue of $23.6M | 3 | Seeking Alpha | ||
| 10.11. | Prenetics Global Limited: Prenetics Reports Record Third Quarter 2025 Results; IM8 on Track for $120M ARR by December 2025, Fastest Supplement Brand Growth in Industry History | 130 | GlobeNewswire (Europe) | Total Revenue Surges 568% YoY to $23.6 million; IM8 Monthly Revenue Hits Record US$9 million in October; Bitcoin Treasury Reaches 387 BTC (~$40M); IM8 Projects $180 - $200M FY 2026 Revenue, $25M... ► Artikel lesen | |
| 10.11. | Prenetics Global Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 07.11. | Prenetics Global's Earnings: A Preview | 1 | Benzinga.com | ||
| 04.11. | Prenetics' IM8 achieves record $9M in revenue for October | 3 | Seeking Alpha | ||
| 31.10. | Prenetics acquires 100 bitcoin following $44M equity raise | 3 | Seeking Alpha | ||
| 31.10. | Prenetics Global Limited: Prenetics Bolsters Bitcoin Treasury with Strategic Acquisition of 100 Bitcoin, IM8 Reaches $100M ARR | 235 | GlobeNewswire (Europe) | Additional Bitcoin Acquisition Follows Immediately on $44 Million Equity OfferingCompany now holds a total of 378 BTC (valued at ~$41 Million)CHARLOTTE, N.C., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Prenetics... ► Artikel lesen | |
| 29.10. | Prenetics Global Limited: Prenetics CEO Danny Yeung Publishes "The Dual-Engine Revolution" Manifesto: A Blueprint for the Future of Health + Wealth | 2 | GlobeNewswire (USA) | ||
| 28.10. | Prenetics Global Limited: Prenetics Announces Closing of Approx. $44.0 Million Equity Offering to Fuel IM8's Global Expansion and Bitcoin Treasury Strategy | 4 | GlobeNewswire (USA) | ||
| 28.10. | Nasdaq-notiertes Unternehmen Prenetics sammelt $48 Millionen ein, um Bitcoin zu kaufen | 4 | Newsbit | ||
| 27.10. | David Beckham-verbundenes Prenetics greift auf Prominente und Krypto-Titanen bei einer $48M-Finanzierung für Bitcoin-Schatz zurück | 2 | Bitcoin.com News | ||
| 27.10. | Prenetics Oversubscribes Offering | - | Baystreet.ca |
1 2 3 Weiter >>
57 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CANSINO BIOLOGICS | 4,060 | -2,40 % | CanSino Biologics Inc: Innovative Vaccine Engine Continues to Drive Growth: CanSinoBIO Enters a New Growth Cycle | HONG KONG, Aug 20, 2025 - (ACN Newswire) - In the first half of 2025, the structural transformation of the pharmaceutical industry continued to deepen. Driven by favorable policies, product upgrades... ► Artikel lesen | |
| SINO BIOPHARM | 0,758 | -0,53 % | SINO BIOPHARM (01177): VOLUNTARY ANNOUNCEMENT - "CULMERCICLIB CAPSULE" APPROVED FOR MARKETING | ||
| GENSCRIPT BIOTECH | 1,437 | -0,17 % | GenScript Biotech Corporation: GenScript Biotech Demonstrates Profitable Scale and Strategic Leadership in H1 2025, Establishing Clear Industry Leadership Through Accelerated Growth and Innovation | Rising Global Footprint, Best-in-Class Innovation, and ESG Excellence Set Stage for Sustained Value Creation
PISCATAWAY, N.J., Aug. 17, 2025 /PRNewswire/ --... ► Artikel lesen | |
| QUANTUM-SI | 1,290 | -7,86 % | Quantum-Si stock rating reiterated by H.C. Wainwright on Proteus potential | ||
| INNOVENT BIOLOGICS | 9,150 | -1,08 % | Innovent Biologics: Mazdutide Demonstrates Significant Weight Loss and Metabolic Benefits in Phase 1b Clinical Trial in Chinese Adolescents with Obesity | After 12 weeks of treatment, the 4 mg and 6 mg mazdutide groups achieved reductions in BMI from baseline of 8.78% and 10.99%, respectively, with corresponding... ► Artikel lesen | |
| SCILEX | 16,630 | -1,25 % | Scilex Holding erweitert Kreditvereinbarung auf 100 Millionen US-Dollar und verpfändet zusätzliche Datavault-AI-Aktien | ||
| ORIGIN AGRITECH | 1,350 | +7,14 % | Origin Agritech Limited: Origin Agritech Obtains New Licenses for Crop Seed Production and GMO Business Operations | Strategic Restructuring Positions Company to Strengthen Market Presence with Expanded Operational Capabilities
BEIJING, Oct. 24, 2025 /PRNewswire/ -- Origin Agritech... ► Artikel lesen | |
| AKESO | 13,300 | -0,75 % | Akeso, Inc.: Cadonilimab (PD-1/CTLA-4) Receives FDA Clearance for Global Phase III First-Line Gastric Cancer Trial Versus Nivolumab | HONG KONG, Dec. 11, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced FDA approval to initiate COMPASSION-37/AK104-311 trial, a global... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 67,06 | -0,56 % | Structure Therapeutics Inc.: Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional ADSs | SAN FRANCISCO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 77,08 | +0,72 % | Apogee Therapeutics stock initiated with Buy rating at Deutsche Bank | ||
| COGENT BIOSCIENCES | 42,110 | +5,17 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) | -- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an objective response rate (CR+CRh+PR+CI) of 57% per mIWG criteria and 80% per PPR criteria -- -- Bezuclastinib... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 40,510 | +2,30 % | Harmony Biosciences Holdings, Inc.: Harmony Biosciences to Present Rare Epilepsy Data at the 36th International Epilepsy Congress | Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that it will present data from its rare epilepsy pipeline at the 36th International Epilepsy Congress (IEC) being held August 30... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 71,83 | +0,32 % | Dyne upgraded at Oppenheimer on upcoming trial readout from Avidity | ||
| LENZ THERAPEUTICS | 18,140 | -25,96 % | LENZ Therapeutics, Inc. - 8-K, Current Report | ||
| QIAGEN | 38,345 | -0,67 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Die Profitabilität dürfte 2026 zumindest stabil bleiben... ► Artikel lesen |
Das Unternehmen PRENETICS GLOBAL LIMITED kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,630 (-4,07 %) liegt der Kurs bei 14,840 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PRENETICS GLOBAL LIMITED finden Sie auf Wallstreet Online.